How do you use daratumumab in the treatment of systemic AL amyloidosis?
What regimens would you consider combining it with?
Any specific combinations to avoid or special considerations?
Answer from: Medical Oncologist at Academic Institution
I now routinely incorporate daratumumab into the frontline treatment for AL amyloidosis as well as in the relapsed/refractory setting. The data supporting frontline use comes from the phase III ANDROMEDA study which randomized patients to Dara-CyBorD to CyBorD (cyclophosphamide, bortezomib, dexameth...
Sign in or Register to read more